JOURNAL of
ONCOLOGICAL
SCIENCES

CASE REPORT

Challenging VIPoma Case Treated with Sunitinib: A Life-Saving Therapeutic Experience
Received Date : 13 Aug 2024
Accepted Date : 30 Sep 2024
Available Online : 10 Oct 2024
Doi: 10.37047/jos.2024-105122 - Article's Language: EN
Journal of Oncological Sciences. 2024;10(3):163-8.
This is an open access article under the CC BY-NC-ND license
ABSTRACT
VIPoma syndrome, a rare neuroendocrine tumor characterized by watery diarrhea, hypokalemia, and achlorhydria, poses a significant clinical challenge due to its life-threatening symptoms and limited treatment options. We present the case of a 44-year-old female with VIPoma, initially unresponsive to standard therapies such as somatostatin analogs and chemotherapy. Despite a challenging treatment course, including loperamide, glucocorticoids, metoclopramide, carboplatin-etoposide chemotherapy the patient’s symptoms persisted. The turning point came with the initiation of sunitinib therapy, leading to a rapid and complete resolution of refractory diarrhea, renal insufficiency, hypotension, and electrolyte imbalances. This case underscores the importance of considering sunitinib as a life-saving treatment in VIPoma patients with resistant symptoms. As VIPoma is a rare entity, collaborative multi-center studies are crucial for enhancing our understanding of its natural course, treatment strategies, and prognosis.
REFERENCES
  1. Schizas D, Mastoraki A, Bagias G, et al. Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review. J BUON. 2019;24(2):415-423. [PubMed] 
  2. Dimitriadis GK, Weickert MO, Randeva HS, et al. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23(9):R423-436. [Crossref]  [PubMed] 
  3. Una Cidon E. Vasoactive intestinal peptide secreting tumour: An overview. World J Gastrointest Oncol. 2022;14(4):808-819. [Crossref]  [PubMed]  [PMC] 
  4. Azizian A, König A, Ghadimi M. Treatment options of metastatic and nonmetastatic VIPoma: a review. Langenbecks Arch Surg. 2022;407(7):2629-2636. [Crossref]  [PubMed]  [PMC] 
  5. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342. [Crossref]  [PubMed]  [PMC] 
  6. Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589-597. [Crossref]  [PubMed] 
  7. Inzani F, Petrone G, Rindi G. The new World Health Organization classification for pancreatic neuroendocrine neoplasia. Endocrinol Metab Clin North Am. 2018;47(3):463-470. [Crossref]  [PubMed] 
  8. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958;25(3):374-380. [Crossref]  [PubMed] 
  9. Pavel M, Öberg K, Falconi M, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844-860. [Crossref]  [PubMed] 
  10. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513. Erratum in: N Engl J Med. 2011;364(11):1082. [Crossref]  [PubMed] 
  11. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337. [PubMed] 
  12. de Mestier L, Walter T, Brixi H, et al. Sunitinib achieved fast and sustained control of VIPoma symptoms. Eur J Endocrinol. 2015;172(1):K1-K3. [Crossref]  [PubMed]